BioMarin Pharmaceutical Inc. (BMRN)
BMRN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/0001048477-26-000004-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BMRN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 1999 |
| SEC CIK | 0001048477 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.2B |
| Net income | $348.9M |
| Operating income | $409.5M |
| Net margin | 10.8% |
| Operating margin | 12.7% |
| Revenue growth | +12.9% |
| Cash | $1.3B |
| Total assets | $7.6B |
| P/E (computed) | 32.2× |
| P/S (computed) | 3.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $736.0M cash; operating cash flow $169.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 193,694,734 (2026-10-26); 192,114,344 a year earlier; 188,368,171 three years earlier. | Cover page 2026-10-26 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $4.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.0B | -$122.8M | $188.2M | $736.0M | $4.2B | $3.7B | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $989.7M | $44.8M | $168.1M | $874.0M | $4.2B | $3.4B | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $766.2M | $105.5M | $220.7M | $2.2B | $1.4B | $3.2B | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $874.6M | -$46.6M | $99.6M | $1.3B | $597.2M | $3.2B | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $776.1M | -$30.7M | $368.7M | $1.3B | $596.7M | $3.1B | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $825.4M | $240.5M | $185.3M | $1.2B | $596.2M | $3.1B | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $745.1M | $185.7M | $174.4M | $1.0B | $595.6M | $3.0B | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $747.3M | $124.9M | $185.6M | $942.8M | $595.1M | $2.9B | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2017-08-09 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-02 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.1% |
| 1 month | +5.2% |
| 3 months | -16.5% |
| Year to date | -3.7% |
| 1 year | +5.6% |
| From 52-week high | -18.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RDY | Dr. Reddy's Laboratories Ltd | $14.70 | -0.27% | $12.3B |
| MDGL | Madrigal Pharmaceuticals Inc. | $423.96 | -0.80% | $9.8B |
| ELAN | Elanco Animal Health Incorporated | $26.41 | -1.38% | $13.2B |
| TGTX | TG Therapeutics Inc. | $62.76 | -2.71% | $9.5B |
| SMMT | Summit Therapeutics Inc. Common Stock | $11.82 | -16.47% | $9.5B |
| SYRE | Spyre Therapeutics Inc. | $99.37 | -4.45% | $9.4B |
| PRAX | Praxis Precision Medicines Inc. | $310.27 | -5.44% | $8.7B |
| BBIO | BridgeBio Pharma Inc. | $77.36 | -1.20% | $15.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier